MIS barriers and corresponding mission governance actions to which actors in the mission arena are committed. Dahkki Joeri Wesseling (16819641)

Fáttát:

Overview of strength and weaknesses of the MIS approach. Dahkki Joeri Wesseling (16819641)

Fáttát:

Overview of interviewees. Dahkki Joeri Wesseling (16819641)

Fáttát:

Primers of this study. Dahkki Shuang Li (146392)

Fáttát:

Agarose gel electrophoresis results of PCR products. Dahkki Shuang Li (146392)

Fáttát:

The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>. Dahkki Shuang Li (146392)

Fáttát:

The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium. Dahkki Shuang Li (146392)

Fáttát:

Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwate... Dahkki Shanhu Xiao (22226759)

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. Dahkki Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Dahkki Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Dahkki Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Dahkki Diana M. Hendrickx (1507435)